Assessing network degeneration and phenotypic heterogeneity in genetic frontotemporal lobar degeneration by decoding FDG-PET
Year: 2023
Type: article
Study design: Observational Study
Abstract: Fluorodeoxyglucose-positron emission tomography (FDG-PET) data from 39 patients with genetic FTLD, including 11 carrying the C9orf72 hexanucleotide expansion, 16 carrying a MAPT mutation and 12 carrying a GRN mutation. We performed a spectral covariance decomposition analysis between FDG-PET images to yield unbiased latent patterns reflective of whole brain patterns of metabolism ("eigenbrains" or EBs). We then conducted linear discriminant analyses (LDAs) to perform EB-based predictions of genetic mutation and predominant clinical phenotype (i.e., behavior/personality, language, asymptomatic). Five EBs were significant and explained 58.52 % of the covariance between FDG-PET images. EBs indicative of hypometabolism in left frontotemporal and temporo-parietal areas distinguished GRN mutation carriers from other genetic mutations and were associated with predominant language phenotypes. EBs indicative of hypometabolism in prefrontal and temporopolar areas with a right hemispheric predominance were mostly associated with predominant behavioral phenotypes and distinguished MAPT mutation carriers from other genetic mutations. The LDAs yielded accuracies of 79.5 % and 76.9 % in predicting genetic status and predominant clinical phenotype, respectively. A small number of EBs explained a high proportion of covariance in patterns of network degeneration across FTLD-related genetic mutations. These EBs contained biological information relevant to the variability in the pathophysiological and clinical aspects of genetic FTLD, and for offering valuable guidance in complex clinical decision-making, such as decisions related to genetic testing.
Source: NeuroImage Clinical
Authors: Nick Corriveau-Lecavalier, Leland R. Barnard, Scott A. Przybelski, Venkatsampath Gogineni, Hugo Botha, Jonathan Graff-Radford, Vijay K. Ramanan, Leah K. Forsberg, Julie A. Fields, Mary M. Machulda, Rosa Rademakers, Ralitza H. Gavrilova, Maria I. Lapid, Bradley F. Boeve, David S. Knopman, Val J. Lowe, Ronald C. Petersen, Clifford R. Jack, Kejal Kantarci, David T. Jones
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,400
Awards: Alzheimers Disease Patient Registry, The Alzheimer's Disease Research Center at the University of California, Irvine, Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system, G9000025891, G9000163348, G9000183948, G9000338148, ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2), Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers, Mayo Alzheimer's Disease Research Center
OpenAlex ID: W4390102297
